Literature DB >> 6244736

Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study.

E Horvath, K Kovacs, D W Killinger, H S Smyth, M E Platts, W Singer.   

Abstract

Among 300 surgically removed pituitary adenomas, 17 tumors containing immunoreactive 1-39 adrenocorticotropin (ACTH) and/or 19-39 ACTH, beta-lipotropin, and alpha-endorphin but unassociated with clinical signs of Cushing's disease have been detected. These neoplasms were divided into basophilic adenomas with strong periodic acid-Schiff (PAS) and lead-hematoxylin positivity and chromophobic tumors with moderate or no PAS and lead-hematoxylin positivity. The former were densely granulated tumors with a fine structure strikingly similar to that of functioning corticotropic cell adenomas. The latter were sparsely granulated with varying ultrastructural patterns. The marked morphologic diversity suggests that these adenomas, despite their similar immunocytologic characteristics, represent more than one entity. Clinically, the most common finding was a rapidly progressing visual defect. An unusually high incidence of infarction (5 cases) and recurrence (5 cases) was noted, underlining the importance of correct morphologic diagnosis and careful follow-up.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244736      PMCID: PMC1903510     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  14 in total

Review 1.  Ultrastructure of human sella tumors. Correlations of clinical findings and morphology.

Authors:  A M Landolt
Journal:  Acta Neurochir (Wien)       Date:  1975       Impact factor: 2.216

2.  Light and electron microscopic features of a pituitary adenoma in Nelson's syndrome.

Authors:  K Kovacs; E Horvath; N A Kerenyi; R H Sheppard
Journal:  Am J Clin Pathol       Date:  1976-03       Impact factor: 2.493

Review 3.  Pituitary adenomas.

Authors:  K Kovacs; E Horvath; C Ezrin
Journal:  Pathol Annu       Date:  1977

4.  [Dissociation of results obtained with an immunofluorescence technique by using anti-ACTH antibodies in three cases of pituitary "chromophobe" adenoma without hypercorticism; ultrastructural study (author's transl)].

Authors:  G Tramu; J C Beauvillain; M Mazzuca; P Fossati; A Martin-Linquette; J L Christiaens
Journal:  Ann Endocrinol (Paris)       Date:  1976 Jan-Feb       Impact factor: 2.478

5.  Pars intermedia basophil adenoma of the hypophysis.

Authors:  A T Rasmussen; A A Nelson
Journal:  Am J Pathol       Date:  1938-05       Impact factor: 4.307

Review 6.  Adenohypophysis: ultrastructural cytochemistry. A review.

Authors:  G C Moriarty
Journal:  J Histochem Cytochem       Date:  1973-10       Impact factor: 2.479

7.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

8.  Demonstration by immunoperoxidase histochemistry of calcitonin in the anterior lobe of the rat pituitary.

Authors:  L J Deftos; D Burton; B D Catherwood; H G Bone; J G Parthemore; R Guillemin; W B Watkins; R Y Moore
Journal:  J Clin Endocrinol Metab       Date:  1978-08       Impact factor: 5.958

9.  Ultrastructural classification of pituitary adenomas.

Authors:  E Horvath; K Kovacs
Journal:  Can J Neurol Sci       Date:  1976-02       Impact factor: 2.104

10.  Localization of prolactin in chromophobe pituitary adenomas: study of human necropsy material by immunoperoxidase technique.

Authors:  K Kovacs; B Corenblum; A M Sirek; G Penz; C Ezrin
Journal:  J Clin Pathol       Date:  1976-03       Impact factor: 3.411

View more
  58 in total

1.  The silent corticotropinoma: is clinical diagnosis possible?

Authors:  B Ambrosi; P Colombo; D Bochicchio; M Bassetti; B Masini; G Faglia
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

2.  Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts.

Authors:  M Shibuya; F Saito; T Miwa; R L Davis; C B Wilson; T Hoshino
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas.

Authors:  J L Jameson; A Klibanski; P M Black; N T Zervas; C M Lindell; D W Hsu; E C Ridgway; J F Habener
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Proliferation of adenohypophyseal cells into posterior lobe. Their normal anatomical condition and possible neoplastic potentiality.

Authors:  S Kuebber; S Ropte; A Hori
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

5.  The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.

Authors:  S M Ekramullah; Y Saitoh; N Arita; T Ohnishi; T Hayakawa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 6.  Intracranial dissemination of pituitary adenoma. Case report and review of the literature.

Authors:  M T Giordana; P Cavalla; A Allegranza; B Pollo
Journal:  Ital J Neurol Sci       Date:  1994-05

7.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

8.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.

Authors:  Marie S Thearle; Pamela U Freda; Jeffrey N Bruce; Steven R Isaacson; Yoomi Lee; Robert L Fine
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

10.  Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.

Authors:  S Ohta; S Nishizawa; Y Oki; T Yokoyama; H Namba
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.